Journal Article

Assessing the Beneficial Impact of a Patient Support Program in Secukinumab-Treated Patients with Psoriasis in Italy

Leporati, Claudia, Amerio, Paolo, Richetta, Antonio Giovanni, Coppola, Simmaco, Uzzauto, Maria Teresa, Castelli, Gianpiero, Argenziano, Giuseppe, Aragone, Maria Grazia, Lembo, Serena, Travaglini, Massimo, Loconsole, Francesco, Peris, Ketty, Giofrè, Claudia, Baldari, Manuela, Tiberio, Rossana, Baggini, Ginevra, Savoia, Paola, Costanzo, Antonio, Malara, Giovanna, Fargnoli, Maria Concetta, Foti, Caterina, Bianchi, Luca, De Pasquale, Rocco

2021

Overview

For patients with psoriasis, treatment adherence and persistence are fundamental if therapeutic goals are to be met. Patient Support Programs (PSPs) may be used as a support tool to assist patients and health care professionals optimize treatment and improve disease management. In Italy, the PSP PSOLife CARE, which began on the 9th of February 2017 and is ongoing, aimed to support patients with psoriasis under therapy with secukinumab (Cosentyx ). A team of medical professionals including Dermatologists, Psychologists, Nutritionists, and field Nurses provided outpatient treatment as well as remote support via phone calls. Patients had a standard duration in the Program of 6 months. This report analyzes the data of patients who benefited from the Program from February 2017 to August 2020, for a total observation of 42 months. We provide here a descriptive report on the benefits of participation in the PSOLife CARE Program for patients with psoriasis and medical professionals involved in their care. Throughout their time in the PSOLife CARE Program, patient satisfaction remained consistently high with sustained improvements observed in all aspects of quality of life (ie emotional, social, physical, and economic). Despite exiting from the Program, most patients continued to adhere to secukinumab. Medical professionals also reported positive outcomes on their interactions with patients, with more than half of those surveyed rating the overall quality of the Program as \"Outstanding\". By supporting treatment adherence, the PSOLife CARE Program may have empowered patients to better manage their psoriasis, increasing their satisfaction with treatment and quality of life.

• Publisher: Dove Medical Press Limited,Taylor & Francis Ltd,Dove Press,Dove,Dove Medical Press
• Subject: Dermatology / Disease management / Drug dosages / Drug therapy / Immune system / Medical personnel and patient / Medical research / Medicine, Experimental / Monoclonal antibodies / Nutritionists / Original Research / Patient compliance / Patient safety / Patient satisfaction / Pharmaceutical industry / Privacy / Professional ethics / PSOLife CARE Program / Psoriasis / Psychologists / Quality of life / treatment adherence